Mobocertinib has entered the medical insurance period, can it be covered by medical insurance?

Mobocertinib (Mobocertinib) is a new generation of targeted therapy for the treatment of non-small cell lung cancer (NSCLC).

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.

Mobosetinib is a targeted therapy for NSCLC patients with EGFR gene mutations. EGFR (epidermal growth factor receptor) is a protein that is frequently mutated in NSCLC and these mutations lead to abnormal growth and division of cancer cells. Mobosetinib is unique in that it is specifically indicated for patients who carry the EGFR T790M mutation, which often results in resistance to other EGFR-targeted therapies.

The mechanism of action of Mobosetinib includes inhibiting the activity ofEGFR protein, thereby effectively preventing the growth and division of cancer cells. Unlike other EGFR-targeted therapies, mobosetinib is highly inhibitory to the EGFR T790M mutation, making it an important treatment option, especially for patients who have previously developed resistance to other drugs.

Side effects of drugs are usually mild and include diarrhea, rash, fatigue, nausea, vomiting, headache, etc. However, some patients may experience serious side effects, such as liver function abnormalities or interstitial pneumonitis. Therefore, patients need to pay close attention and stay in contact with their doctors to ensure safe treatment.